Literature DB >> 8059701

Natural history of the asymptomatic/minimally symptomatic patient with severe mitral regurgitation secondary to mitral valve prolapse and normal right and left ventricular performance.

S E Rosen1, J S Borer, C Hochreiter, P Supino, M J Roman, R B Devereux, P Kligfield, J Bucek.   

Abstract

The natural history of patients with severe nonischemic mitral regurgitation (MR) from mitral valve prolapse, who are asymptomatic or minimally symptomatic and have normal right ventricular (RV) and left ventricular (LV) performance, has not been evaluated previously. To define natural history in this population and to determine if any objective variables could predict disease progression, 31 patients were followed annually with severe MR due to prolapse, who at entry were asymptomatic or minimally symptomatic and had normal RV and LV performance at rest by radionuclide cineangiography. Average follow-up in patients not reaching surgical end point was 4.7 years. The Kaplan-Meier product limit estimates were used to determine the rate of progression to either "operable" symptoms or to previously defined "high risk" ventricular performance descriptors, if the latter occurred first. Univariate comparisons of Kaplan-Meier curves and multivariate Cox proportional hazards analyses were used to define prognostically important variables measured at entry. Fourteen patients developed symptoms warranting referral for operation; none developed high-risk ventricular performance descriptors. The annual end point risk was 10.3%. Of all covariates, only change in RV ejection fraction from rest to exercise was significantly associated with disease progression. Annual risk of progression to surgical end point was 4.9% in the subgroup in which this parameter increased with exercise and 14.7% in the subgroup without an increase (p = 0.04). Patients with severe MR due to mitral valve prolapse, who are asymptomatic or minimally symptomatic with normal ventricular performance, can be expected to progress to surgical indications at an annual rate of 10.3%.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Year:  1994        PMID: 8059701     DOI: 10.1016/0002-9149(94)90406-5

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  16 in total

1.  A method for the morphological analysis of the regurgitant mitral valve using three dimensional echocardiography.

Authors:  A Macnab; N P Jenkins; I Ewington; B J M Bridgewater; T L Hooper; D L Greenhalgh; M R Patrick; S G Ray
Journal:  Heart       Date:  2004-07       Impact factor: 5.994

2.  Mitral repair best practice: proposed standards.

Authors:  B Bridgewater; T Hooper; C Munsch; S Hunter; U von Oppell; S Livesey; B Keogh; F Wells; M Patrick; J Kneeshaw; J Chambers; N Masani; S Ray
Journal:  Heart       Date:  2005-10-26       Impact factor: 5.994

Review 3.  Quantitative assessment of mitral insufficiency: its advantages and disadvantages.

Authors:  Anna Paszczuk; Susan E Wiegers
Journal:  Heart Fail Rev       Date:  2006-09       Impact factor: 4.214

4.  Prognostic value of exercise tolerance testing in asymptomatic chronic nonischemic mitral regurgitation.

Authors:  Phyllis G Supino; Jeffrey S Borer; Karlheinz Schuleri; Anuj Gupta; Clare Hochreiter; Paul Kligfield; Edmund McM Herrold; Jacek J Preibisz
Journal:  Am J Cardiol       Date:  2007-07-23       Impact factor: 2.778

Review 5.  Management decisions in valvular heart disease: the role of radionuclide-based assessment of ventricular function and performance.

Authors:  J S Borer; D Wencker; C Hochreiter
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

6.  Management of asymptomatic, severe mitral regurgitation.

Authors:  Dina M Sparano; R Parker Ward
Journal:  Curr Treat Options Cardiovasc Med       Date:  2012-12

7.  Nonischemic mitral regurgitation: prognostic value of nonsustained ventricular tachycardia after mitral valve surgery.

Authors:  Oladipupo Olafiranye; Clare A Hochreiter; Jeffrey S Borer; Phyllis G Supino; Edmund M Herrold; Adam S Budzikowski; Ofek Y Hai; Dany Bouraad; Paul D Kligfield; Leonard N Girardi; Karl H Krieger; O Wayne Isom
Journal:  Cardiology       Date:  2013-02-20       Impact factor: 1.869

8.  The use of exercise echocardiography in the evaluation of mitral regurgitation.

Authors:  Kibar Yared; Kaitlyn My-Tu Lam; Judy Hung
Journal:  Curr Cardiol Rev       Date:  2009-11

9.  Assessment of cardiac remodeling in asymptomatic mitral regurgitation for surgery timing: a comparative study of echocardiography and magnetic resonance imaging.

Authors:  Oner Ozdogan; Alper Yuksel; Cemil Gurgun; Meral Kayikcioglu; Oguz Yavuzgil; Cahide S Cinar
Journal:  Cardiovasc Ultrasound       Date:  2010-08-13       Impact factor: 2.062

10.  Percutaneous approaches to mitral regurgitation.

Authors:  Faisal Alqoofi; Ted Feldman
Journal:  Curr Treat Options Cardiovasc Med       Date:  2009-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.